Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for ...

Roche is in talks with the US government to cut out the pharmaceutical industry's intermediaries and sell medicines directly ...

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...

Swiss pharmaceutical giant Roche on Thursday posted better-than-expected net income for the first half of 2025 amid strong ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...

Roche Holding AG said on Tuesday it has paused shipments of muscular disorder gene therapy Elevidys in some countries outside ...

Roche obtained CT-173, a PYY mimetic, in its $2.7 billion acquisition of Carmot Therapeutics in December 2023. The company ...

We’re gonna get the drug prices down – not 30% or 40%. No, we’re gonna get them down 1,000%, 1,500%,” said the US president.